Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Janux Therapeutics, Inc. Market Cap
From what 0 stock analysts predict, the share price for Janux Therapeutics, Inc. (JANX) might increase by 52.82% in the next year. This is based on a 12-month average estimation for JANX. Price targets go from $42 to $100. The majority of stock analysts believe JANX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned JANX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Janux Therapeutics, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on JANX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of JANX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Josh Schimmer Cantor Fitzgerald | Overweight | $100 | Reiterates | Sep 16, 2024 |
| Bradley Canino Stifel | Buy | $70 | Initiates | Sep 6, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $63 | Reiterates | Aug 19, 2024 |
| George Farmer Scotiabank | Sector Perform | $42 | Maintains | Aug 9, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $100 | Reiterates | Aug 8, 2024 |
| Robert Driscoll Wedbush | Outperform | $74 | Reiterates | Aug 8, 2024 |
| George Farmer Scotiabank | Sector Perform | $47 | Initiates | May 30, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $63 | Maintains | May 13, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $100 | Reiterates | May 9, 2024 |
| Robert Driscoll Wedbush | Outperform | $74 | Maintains | May 8, 2024 |
| Soumit Roy JonesTrading | Buy | $70 | Initiates | Apr 16, 2024 |
| Kaveri Pohlman BTIG | Buy | $62 | Initiates | Mar 21, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $100 | Initiates | Mar 20, 2024 |
| Geoff Meacham B of A Securities | Buy | $48 | Maintains | Mar 13, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $50 | Maintains | Mar 11, 2024 |
| David Driscoll Wedbush | Outperform | $53 | Maintains | Feb 27, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $35 | Reiterates | Nov 13, 2023 |
| Robert Driscoll Wedbush | Outperform | $24 | Reiterates | Nov 8, 2023 |
| Robert Driscoll Wedbush | Outperform | $24 | Reiterates | Aug 10, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $35 | Reiterates | Aug 9, 2023 |
When did it IPO
2021
Staff Count
69
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. David Alan Campbell Ph.D.
Market Cap
$2.32B
In 2023, JANX generated $8.1M in revenue, which was a decrease of -6.14% from the previous year. This can be seen as a signal that JANX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 13 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Janux Therapeutics (JANX) saw a share price increase on higher trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
Why It Matters - The jump in Janux Therapeutics' share price indicates short-term investor interest, but stagnant earnings estimates may signal potential future weakness, prompting caution.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Janux Therapeutics reported its second quarter 2024 financial results and highlighted key business developments.
Why It Matters - Janux Therapeutics' Q2 2024 results may indicate financial health and growth potential, impacting stock performance and investor sentiment in the biotech sector.
Wed, 07 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Janux Therapeutics (JANX) reported a quarterly loss of $0.11 per share, beating the Zacks estimate of $0.32 and improving from a loss of $0.42 per share a year prior.
Why It Matters - Janux Therapeutics' smaller-than-expected loss indicates improved financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Mon, 22 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Janux Therapeutics (Nasdaq: JANX) announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors, enhancing its leadership in biopharmaceuticals.
Why It Matters - The appointment of experienced leaders to Janux Therapeutics' board can enhance strategic direction and decision-making, potentially increasing investor confidence and stock value.
Wed, 26 Jun 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Janux Therapeutics is developing immunotherapies targeting PSMA and EGFR, with promising clinical results. JANX007 led to a 50% PSA reduction in 83% of mCRPC patients, and JANX008 achieved 100% lung tumor reduction in one NSCLC patient.
Why It Matters - Janux Therapeutics' promising clinical results for JANX007 and JANX008 highlight potential for significant market impact, increasing investor interest in the company's growth and future profitability.
Tue, 07 May 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Janux Therapeutics reported its Q1 2024 financial results and highlighted key business developments. Further details on performance metrics are available in the full report.
Why It Matters - Janux Therapeutics' Q1 2024 financial results and business highlights provide insights into its performance and strategic direction, influencing investor confidence and stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
